Date: 2019-09-30

Type of information: Nomination

Compound: senior vice president, chief medical officer

Company: Sangamo Therapeutics (USA - CA)

Therapeutic area:

Type agreement: nomination

Action mechanism:



  • • On September 30, 2019, Sangamo Therapeutics, announced the appointment of Bettina M. Cockroft, as Senior Vice President and Chief Medical Officer. Dr. Cockroft will oversee all clinical development activities and operations and will report to the Executive Vice President of Research and Development.
  • Dr. Cockroft has 23 years of experience in the biopharmaceutical industry and joins Sangamo from Cytokinetics, where she was a member of the senior leadership team responsible for clinical development of fast skeletal muscle troponin activators in diseases such as Amyotrophic Lateral Sclerosis and Spinal Muscular Atrophy. Before that, Dr. Cockroft served as Chief Medical Officer of Auris Medical AG, where she led and grew the clinical development team responsible for two Phase 3 programs. Dr. Cockroft also held roles of increasing responsibility at Merck Serono S.A., Novartis Consumer Health and Menarini Ricerche earlier in her career. Dr. Cockroft earned her MBA at MIT Sloan School of Management and her MD from the University of Genoa.

Financial terms:

Latest news:

Is general: Yes